1. Home
  2. VTSI vs ALXO Comparison

VTSI vs ALXO Comparison

Compare VTSI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirTra Inc.

VTSI

VirTra Inc.

HOLD

Current Price

$4.49

Market Cap

61.9M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.42

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTSI
ALXO
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.9M
79.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VTSI
ALXO
Price
$4.49
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$7.00
$3.30
AVG Volume (30 Days)
53.9K
255.4K
Earning Date
11-10-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$24,934,267.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.39
N/A
P/E Ratio
$331.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.57
$0.40
52 Week High
$7.49
$2.27

Technical Indicators

Market Signals
Indicator
VTSI
ALXO
Relative Strength Index (RSI) 30.19 49.15
Support Level $4.79 $1.29
Resistance Level $4.94 $1.57
Average True Range (ATR) 0.14 0.11
MACD -0.02 0.01
Stochastic Oscillator 9.05 55.00

Price Performance

Historical Comparison
VTSI
ALXO

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: